Intra-Cellular Therapies: Q2 Earnings Insights

Intra-Cellular Therapies ITCI reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Intra-Cellular Therapies missed estimated earnings by 21.05%, reporting an EPS of $-0.92 versus an estimate of $-0.76.

Revenue was up $35.53 million from the same period last year.

Last quarter the company beat on EPS by $0.14 which was followed by a 0.26% increase in the share price the next day.

Here's a look at Intra-Cellular Therapies's past performance:

Quarter	Q1 2022	Q4 2021	Q3 2021	Q2 2021
EPS Estimate	-0.92	-1	-0.92	-0.80
EPS Actual	-0.78	-1.05	-0.95	-0.85
Revenue Estimate	33.65M	25.37M	22.12M	19.44M
Revenue Actual	35.00M	25.67M	22.21M	20.05M

To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar